Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zosano Pharma Corporation ZSANQ

Healthcare Biotechnology
Zosano Pharma Corp is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Zosano Pharma Corp is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K... see more

Recent & Breaking News (EXPM:ZSANQ)

Zosano Announces Pricing of Registered Direct Offering

GlobeNewswire November 27, 2019

Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire November 14, 2019

Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta(TM)

GlobeNewswire November 13, 2019

Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update

GlobeNewswire November 7, 2019

Zosano Pharma Initiates Phase 2/3 Clinical Study in Cluster Headache

GlobeNewswire October 24, 2019

Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 23, 2019

Zosano Pharma Announces CEO Transition

GlobeNewswire October 8, 2019

Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 27, 2019

Zosano Pharma to Present at the Cantor Global Healthcare Conference

GlobeNewswire September 26, 2019

Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development

GlobeNewswire September 18, 2019

Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta(TM) Long-Term Safety Study at the Congress of the International Headache Society

GlobeNewswire September 9, 2019

Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire September 3, 2019

Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society

GlobeNewswire August 23, 2019

Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2019

Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache

GlobeNewswire August 14, 2019

Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update

GlobeNewswire August 7, 2019

Zosano Pharma Presents Migraine-ACT Scores for Qtrypta(TM) at the American Headache Society (AHS) Annual Scientific Meeting

GlobeNewswire July 15, 2019

Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference

GlobeNewswire July 3, 2019

Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting

GlobeNewswire July 1, 2019

Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta(TM)

GlobeNewswire June 18, 2019